S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain

Invitae (NVTA) Competitors

$0.01
0.00 (0.00%)
(As of 02/22/2024 ET)

NVTA vs. OPGN, BGLC, PMD, BPTH, OBSV, STSS, XCUR, NSTG, SONN, and KPRX

Should you be buying Invitae stock or one of its competitors? The main competitors of Invitae include OpGen (OPGN), BioNexus Gene Lab (BGLC), Psychemedics (PMD), Bio-Path (BPTH), ObsEva (OBSV), Sharps Technology (STSS), Exicure (XCUR), NanoString Technologies (NSTG), Sonnet BioTherapeutics (SONN), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "medical" sector.

Invitae vs.

OpGen (NASDAQ:OPGN) and Invitae (NYSE:NVTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.

Invitae has a consensus target price of $1.00, indicating a potential upside of 7,307.41%. Given OpGen's higher possible upside, analysts clearly believe Invitae is more favorable than OpGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Invitae
3 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

13.1% of OpGen shares are owned by institutional investors. Comparatively, 61.3% of Invitae shares are owned by institutional investors. 1.3% of OpGen shares are owned by company insiders. Comparatively, 0.7% of Invitae shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Invitae has a net margin of -299.14% compared to Invitae's net margin of -852.18%. Invitae's return on equity of -316.30% beat OpGen's return on equity.

Company Net Margins Return on Equity Return on Assets
OpGen-852.18% -316.30% -89.52%
Invitae -299.14%-6,100.71%-19.68%

In the previous week, Invitae had 1 more articles in the media than OpGen. MarketBeat recorded 2 mentions for Invitae and 1 mentions for OpGen. Invitae's average media sentiment score of 0.00 equaled OpGen'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OpGen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Invitae
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Invitae received 150 more outperform votes than OpGen when rated by MarketBeat users. Likewise, 61.61% of users gave Invitae an outperform vote while only 56.90% of users gave OpGen an outperform vote.

CompanyUnderperformOutperform
OpGenOutperform Votes
301
56.90%
Underperform Votes
228
43.10%
InvitaeOutperform Votes
451
61.61%
Underperform Votes
281
38.39%

OpGen has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

OpGen has higher earnings, but lower revenue than Invitae. OpGen is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OpGen$2.61M1.63-$37.28M-$6.51-0.07
Invitae$481.58M0.01-$3.11B-$5.380.00

Summary

Invitae beats OpGen on 11 of the 16 factors compared between the two stocks.


Get Invitae News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVTA vs. The Competition

MetricInvitaeMedical laboratories IndustryMedical SectorNYSE Exchange
Market Cap$3.61M$1.81B$5.03B$17.52B
Dividend YieldN/A1.88%2.92%3.57%
P/E Ratio0.004.4499.8022.03
Price / Sales0.0151.203,102.347.30
Price / CashN/A8.1388.2517.97
Price / Book0.033.104.365.92
Net Income-$3.11B-$139.28M$112.59M$870.05M
7 Day PerformanceN/A-5.75%0.78%-0.28%
1 Month PerformanceN/A1.55%6.77%2.19%
1 Year PerformanceN/A-18.08%8.71%88.05%

Invitae Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPGN
OpGen
0 of 5 stars
$0.44
-4.3%
N/A-58.4%$4.40M$2.61M-0.0785
BGLC
BioNexus Gene Lab
0 of 5 stars
$0.83
-19.4%
N/AN/A$14.70M$10.93M-41.5927Gap Down
PMD
Psychemedics
0 of 5 stars
$3.17
+6.7%
N/A-43.9%$18.39M$25.24M-4.66133Gap Up
BPTH
Bio-Path
0.6616 of 5 stars
$0.42
-2.3%
N/A-84.2%$5.24MN/A-0.2110Analyst Report
Stock Split
News Coverage
Gap Down
OBSV
ObsEva
0 of 5 stars
$0.07
flat
N/A-52.7%$5.15M$20.11M-0.0748Gap Up
STSS
Sharps Technology
1.8206 of 5 stars
$0.34
+6.3%
N/A-72.2%$5.13MN/A0.0058Gap Up
XCUR
Exicure
2.758 of 5 stars
$0.59
-1.7%
N/A-47.4%$5.11M$28.83M0.357News Coverage
NSTG
NanoString Technologies
3.1585 of 5 stars
N/A$7.63
+∞
N/A$5.07M$127.26M-0.03550Upcoming Earnings
Analyst Report
Gap Down
SONN
Sonnet BioTherapeutics
0.9757 of 5 stars
$1.65
+1.9%
$88.70
+5,275.8%
-90.6%$5.07M$150,000.000.0012Gap Up
KPRX
Kiora Pharmaceuticals
2.1737 of 5 stars
$0.66
+3.1%
$7.00
+963.8%
-89.1%$5.06MN/A0.0012Positive News
Gap Down

Related Companies and Tools

This page (NYSE:NVTA) was last updated on 2/24/2024 by MarketBeat.com Staff